Krina Patel, MD, MSc, on Anitocabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma
ASH 2025
Krina Patel, MD, MSc, of The University of Texas MD Anderson Cancer Center, provides updated results from the fully enrolled, ongoing iMMagine-1 phase II registrational trial of anitocabtagene autoleucel, an autologous anti-BCMA CAR T-cell therapy with a novel D-domain binder. The agent is under development for patients with relapsed and/or refractory multiple myeloma (Abstract 256).
The ASCO Post Staff
The telomerase inhibitor imetelstat was approved for the treatment of certain patients with lower-risk myelodysplastic syndromes (MDS) based on the results of the phase III IMerge trial. Valeria Santini, MD, of the University of Florence, provides updates on secondary endpoints, including overall and progression-free survival; progression to acute myeloid leukemia; safety; and long-term outcomes by subgroups of interest in IMerge, as well as ad hoc outcomes, including overall survival by response (Abstract 2074).
The ASCO Post Staff
Jennifer Woyach, MD, of The Ohio State University Comprehensive Cancer Center, discusses results from the first head-to-head comparison of pirtobrutinib vs ibrutinib in treatment-naive patients and patients with covalent Bruton tyrosine kinase inhibitor–naive relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (Abstract 683).
The ASCO Post Staff
Aaron Logan, MD, PhD, of UCSF Health, discusses research examining the effect of transplant before or after treatment with brexucabtagene autoleucel in the real world for adult patients with relapsed or refractory Philadelphia chromosome–negative B-cell acute lymphoblastic leukemia (ALL) (Abstract 516).
The ASCO Post Staff
Amir Fathi, MD, of Massachusetts General Hospital, discusses data from the phase II PARADIGM trial, which prospectively tested whether azacitidine plus venetoclax was superior to intensive induction chemotherapy in fit patients with newly diagnosed acute myeloid leukemia (AML)—and could challenge the current treatment standard (Abstract 6).
The ASCO Post Staff
Brian Ball, MD, of City of Hope, presents updated results from the phase I/II BEXMAB study. They showed that the doublet had encouraging activity in patients with TP53-mutant, higher-risk MDS; translational data support the combination regimen’s potential for altering immune dysregulation in this subtype (Abstract 236).
